You are here: Industry Insights > NVX-CoV2373

News List

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine prnasia
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO)...
European Commission grants conditional marketing authorization for Novavax COVID-19 vaccine WorldPharmaNews
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC)...
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine prnewswire
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA)...
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine prnasia
December 17, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the submission of a New Drug Application (NDA)...
Novavax seeks interim authorisation for Covid-19 vaccine in Singapore Pharmaceutical-Technology
November 26, 2021
US-based biotechnology firm Novavax has filed an application seeking interim authorisation from the Singapore Health Sciences Authority (HSA) for its Covid-19 vaccine, NVX-CoV2373, under the Pandemic Special Access Route.
Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore prnewswire
November 25, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission...
Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization prnasia
November 18, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that...
Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373 prnasia
November 16, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience)...
Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia prnasia
November 01, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion...
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom prnasia
October 28, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion...

Previous page 1 2 3 4 5 6 7 Next page